FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
Season 3, Episode 43, Oct 01, 2020, 07:56 PM
In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.